Tscan Therapeutics Inc’s recent filing unveils that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $0.29 million on Dec 13 ’24. In the deal valued at $2.90 per share,100,000 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 5,357,347 shares worth roughly $6.64 million.
Then, Lynx1 Capital Management LP bought 31,800 shares, generating $95,629 in total proceeds. Upon buying the shares at $3.01, the 10% Owner now owns 5,257,347 shares.
Before that, Lynx1 Capital Management LP bought 947 shares. Tscan Therapeutics Inc shares valued at $4,114 were divested by the 10% Owner at a price of $4.34 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 5,225,547 shares, worth roughly $6.48 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Monday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock unchanged to $1.24. Over the last five days, the stock has lost -9.49%. Tscan Therapeutics Inc shares have fallen nearly -59.21% since the year began. Nevertheless, the stocks have fallen -86.11% over the past one year. While a 52-week high of $9.69 was reached on 01/03/25, a 52-week low of $1.02 was recorded on 04/09/25.
How much short interest is there in Tscan Therapeutics Inc?
A steep rise in short interest was recorded in Tscan Therapeutics Inc stocks on 2025-04-30, dropping by -0.23 million shares to a total of 1.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 2.03 million shares. There was a decline of -12.91%, which implies that there is a negative sentiment for the stock.
